Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

QIWI reported for 2022

3/31/23 QIWI

Magnit reported for 2022 according to RAS

3/31/23 MGNT

Bank Kuznetsky reported for 2022 according to RAS

3/31/23 KUZB

The AT&T announced a quarterly dividend

3/31/23 T

Aeroflot has no plans to pay dividends for 2022

3/31/23 AFLT

Chelyabinsk Forge-and-Press Plant reported for 2022 according to RAS

3/31/23 CHKZ

Kostroma Sales Company reported for 2022 according to RAS

3/31/23 KTSB

TGC-2 reported for 2022 according to RAS

3/31/23 TGKB

MMK quits steel center project for automotive industry with Turkish Coskunoz in Tatarstan

3/31/23 MAGN

Kazanorgsintez demands ₽9.5 billion advance payment from Siemens for CCGT construction

3/31/23 KZOS